塔达拉菲尔在患有慢性左结子分支障碍的患者中使用的Tadalafil引发的快速肺
Renat Roytenberg1, Oscar Rodrigo Zamudio Herrera1
1Department of Cardiology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Cureus
|September 22, 2025
概括
这份病例报告强调了一名使用塔达拉菲尔的患者的闪发性肺 (FPE). 对于心脏病患者来说,及时识别和管理,包括氧气和尿液,至关重要.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 一名61岁的男性患有失控的高血压,2型糖尿病,脂质失调以及慢性完整的左捆分支阻塞,呈现出急性呼吸困扰.
- 患者的症状开始在使用tadalafil后两个小时,这是一种固酶5型抑制剂.
研究的目的:
- 讨论在患有先前心脏异常的患者中诊断和治疗闪发性肺水腫 (FPE).
- 强调在给有风险的人群开处固酶5型抑制剂时需要谨慎.
主要方法:
- 临床表现和患者病史审查.
- 诊断评估,包括对低氧化和扩散性肺的评估.
- 心声学和组织多普勒成像,以评估心脏功能.
- 管理包括氧气治疗,尿液注射和停止服用塔达拉菲尔.
主要成果:
- 患者出现了急性呼吸困扰和低氧化症.
- 心声图显示了正常的缩功能和I级的透缩功能障碍.
- 症状通过医疗管理和停止服用塔达拉菲尔而消失.
结论:
- 随着5型固酶抑制剂的使用,心脏病患者可能出现闪发性肺 (FPE).
- 迅速识别和管理对于有利的结果至关重要.
- 建议在给有结构性或导电性心脏异常的患者开处方时谨慎.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
567
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
567
Pulmonary Embolism I: Introduction
521
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
521
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
447
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
447
Coronary Artery Disease III: Clinical Manifestations
330
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
330
Heart Failure III: Clinical Manifestations
511
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
511
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
329
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
329


